ReviewFrontiers in immunology2021
Mesenchymal Stem Cells and Tuberculosis: Clinical Challenges and Opportunities.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 21 citations in OpenAlex.
- Role of mesenchymal stem cells and their derived exosomes in cervical cancer: Bidirectional mechanisms and research progress (Review).Oncology letters · 2026Review
- Current research progress on extracellular vesicles derived from mesenchymal stem cells in tuberculosis treatment (Review).Molecular medicine reports · 2026Review
- Investigation of the relationship between chronic hepatitis B and tuberculosis using bioinformatics and systems biology approaches.Frontiers in medicine · 2025Article
- Human mesenchymal stromal cells inhibitThorax · 2024Article
- Mesenchymal stem cells-derived extracellular vesicles for therapeutics of renal tuberculosis.Scientific reports · 2024Article
- Mesenchymal stromal cell-based therapy in lung diseases; from research to clinic.American journal of stem cells · 2024Review
- Comparison of Autografts and Biodegradable 3D-Printed Composite Scaffolds with Osteoconductive Properties for Tissue Regeneration in Bone Tuberculosis.Biomedicines · 2023Article
- Antibiotic Resistance toAntibiotics (Basel, Switzerland) · 2022Review
- Alternatives to Antibiotics againstAntibiotics (Basel, Switzerland) · 2022Review
- Mesenchymal stem/stromal cells in the pathogenesis and regenerative therapy of inflammatory bowel diseases.Frontiers in immunology · 2022Review
- Mesenchymal Stem Cell-Derived Exosome Therapy of Microbial Diseases: From Bench to Bed.Frontiers in microbiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) is one of the communicable diseases caused by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.